Literature DB >> 8625295

Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer.

T M Trybus1, A C Burgess, K J Wojno, T W Glover, J A Macoska.   

Abstract

Utilizing tissue microdissection and PCR techniques, we have examined 35 prostate tumors paired with normal tissues from the same patients for allelic loss at 24 polymorphic loci spanning chromosome 10. Twenty-five tumors (71%) were deleted for at least one chromosome 10 locus. Of the total 35 tumors, 6 (17%) were deleted for 10p loci only, 5 (14%) for 10q loci only, and 14 (40%) were deleted for both 10p and 10q loci. The common region of deletion on 10p included loci D10S211-D10S89-D10S111. Fluorescence in situ hybridization of yeast artificial chromosome probes encompassing these loci demonstrated that the 10p region of deletion maps to 10p11.2. Losses involving 10p loci alone were most common in localized (5/14, 36%) and least common in metastatic (0/8) tumors. The common region of deletion on 10q included loci D10S219-D10S215, consistent with the major region of deletion recently defined for prostate tumors on 10q. Losses involving 10q loci alone were lowest in localized and locally invasive tumors (1/14 and 2/12, respectively) and highest in tumors metastatic to regional lymph nodes (2/8). These results suggest that 10p losses may define less invasive tumors, whereas 10q losses may play a role in the progression to more advanced tumor states in the prostate. Furthermore, this is the first report of allelic loss of a defined region on 10p potentially harboring tumor suppressor gene loci in human prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8625295

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Genetic analysis of prostatic atypical adenomatous hyperplasia (adenosis).

Authors:  J A Doll; X Zhu; J Furman; Z Kaleem; C Torres; P A Humphrey; H Donis-Keller
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

2.  Alleletyping of an oligodendrocyte-type-2 astrocyte lineage derive from a human glioblastoma multiforme.

Authors:  X Mao; R Barfoot; R A Hamoudi; M Noble
Journal:  J Neurooncol       Date:  1998-12       Impact factor: 4.130

Review 3.  Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy.

Authors:  Jennifer Wu; Evan Yu
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

4.  Genetics of prostate cancer.

Authors:  Kai Qi Zhang; Sherry A Salzman; D J Reding; Brian K Suarez; William J Catalona; James K Burmester
Journal:  Clin Med Res       Date:  2003-01

5.  Loss of expression of human spectrin src homology domain binding protein 1 is associated with 10p loss in human prostatic adenocarcinoma.

Authors:  J A Macoska; J Xu; D Ziemnicka; T S Schwab; M A Rubin; L Kotula
Journal:  Neoplasia       Date:  2001 Mar-Apr       Impact factor: 5.715

Review 6.  Review of allelic loss and gain in prostate cancer.

Authors:  G S Bova; W B Isaacs
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

7.  A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49.

Authors:  Lawrence D True; Kent Buhler; Janna Quinn; Emily Williams; Peter S Nelson; Nigel Clegg; Jill A Macoska; Thomas Norwood; Alvin Liu; William Ellis; Paul Lange; Robert Vessella
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

8.  Chronic chlorpyrifos exposure does not promote prostate cancer in prostate specific PTEN mutant mice.

Authors:  Robert U Svensson; Nadine L Bannick; Maximo J Marin; Larry W Robertson; Charles F Lynch; Michael D Henry
Journal:  J Environ Pathol Toxicol Oncol       Date:  2013       Impact factor: 3.567

9.  KLF6 induces apoptosis in prostate cancer cells through up-regulation of ATF3.

Authors:  Xiangwei Huang; Xia Li; Bin Guo
Journal:  J Biol Chem       Date:  2008-08-28       Impact factor: 5.157

10.  Deletion, mutation, and loss of expression of KLF6 in human prostate cancer.

Authors:  Ceshi Chen; Eija-Riitta Hyytinen; Xiaodong Sun; Heikki J Helin; Pasi A Koivisto; Henry F Frierson; Robert L Vessella; Jin-Tang Dong
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.